This year's Biomedical HIV Prevention Summit in Atlanta emphasized the importance of advancing prevention in the U.S. South, a region disproportionately impacted by HIV.
We’re focused on driving innovation in virology, oncology and immunology – and that includes investing in world-class science to change the way cancer is treated.
At Gilead, putting people first is central to all we do. That’s why we’re proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries.
As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with various healthcare systems and has a keen interest in researching patient-centered care models and innovative digital healthcare tools.
We’re proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to operate responsibly and empower our employees to help create a healthier world for all.
In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing Gilead closer to a cure for HIV.
Lauren Huffmaster received a late-stage metastatic breast cancer (mBC) diagnosis in 2015 and soon discovered there wasn’t a lot information to help explain to her young children what she was going through.
Each scientific discovery gets us one step closer to our shared goal of ending the HIV epidemic. As a leader in HIV treatment and prevention, we’ll continue to build on our legacy and create innovative solutions to address the diverse needs of all people affected by HIV.
Through our community partnerships in low-and-middle-income countries, we are working together to expand access and reduce barriers to care while embracing innovation.
We're proud to have contributed to this milestone announced by the World Health Organization - marking the elimination of visceral leishmaniasis (VL) as a public health problem in Bangladesh.
Since the pledge, Gilead has continued its long history in supporting reducing deaths from VL and controlling other neglected tropical diseases such as cryptococcal meningitis in efforts to advance global health equity.
Dr. Shringar Rao’s inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs.
Claudia Hardy says she’s found her life’s mission. As director of Community Health Access and Relations for the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, she brings cancer resources and preventive care to communities.
Gilead Sciences, Inc. (Nasdaq: GILD) was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new report released by Funders Concerned About AIDS (FCAA).
Shortly after Sandra joined Gilead, this company ambition touched close to home. She worked on an acquisition that ended up being the backbone of Gilead’s work to develop a cure for hepatitis C.
Over the years, Gilead has thoughtfully and boldly focused on communities with the greatest unmet needs, and women and girls – in particular, Black women and girls – are always at the top of the list.
This year marks the fifth anniversary of the Gilead COMPASS Initiative®, a 10-year, more than $100 million commitment to addressing the HIV epidemic in the Southern United States.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...